Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: Bench to bedside investigation of pH-dependent solubility

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4074-4081

  Ware, Joseph A ^a   Dalziel, Gena ^a   Jin, Jin Y ^a   Pellett, Jackson D ^a   Smelick, Gillian S ^a   West, David A ^a   Salphati, Laurent ^a   Ding, Xiao ^a   Sutton, Rebecca ^a   Fridyland, Jane ^a   Dresser, Mark J ^a   Morrisson, Glenn ^a   Holden, Scott N ^a  

^a GENENTECH INC   (United States)

Author keywords

acid reducing agents (ARA); drug absorption; drug development; drug drug interaction (DDI); gastric pH; H2 receptor antagonists (H2RA); molecular targeted agents; oral anti cancer therapy; physicochemical; proton pump inhibitor (PPI)

Indexed keywords

PICTILISIB; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FOOD; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PH; PHASE 1 CLINICAL TRIAL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HYDROGEN-ION CONCENTRATION; INDAZOLES; PROTON PUMP INHIBITORS; RABEPRAZOLE; SOLUBILITY; SULFONAMIDES;

EID: 84887395636     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4005595     Document Type: Article

References (22)

1. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-36
2. Wienkers, L. C.; Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005, 4 (10) 825-33
3. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations; 2012.
4. US Food and Drug Administration. Dasatinib (Sprycel) Prescribing Information; 2013.
5. Budha, N. R.; Frymoyer, A.; Smelick, G. S.; Jin, J. Y.; Yago, M. R.; Dresser, M. J.; Holden, S. N.; Benet, L. Z.; Ware, J. A. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clinical Pharmacol. Ther. 2012, 92 (2) 203-13
6. Sparreboom, A.; Verweij, J. Advances in cancer therapeutics Clinical Pharmacol. Ther. 2009, 85 (2) 113-7
7. Smelick, G. S.; Heffron, T.; Chu, L.; Dean, B.; West, D. A.; DuVall, S. L.; Lum, B. L.; Budha, N.; Holden, S. N.; Benet, L. Z.; Frymoyer, A.; Dresser, M. J.; Ware, J. A. Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development Mol. Pharmaceutics 2013, 10.1021/mp400403s
8. Kang, S. P.; Ratain, M. J. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products Clin. Cancer Res. 2010, 16 (17) 4446-51
9. Szmulewitz, R. Z.; Ratain, M. J. Playing Russian roulette with tyrosine kinase inhibitors Clin. Pharm. Ther. 2013, 93 (3) 242-4
10. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nature Rev. Cancer 2009, 9 (8) 550-62
11. Luo, J.; Manning, B. D.; Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 2003, 4 (4) 257-62
12. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K pathway as drug target in human cancer J. Clin. Oncol. 2010, 28 (6) 1075-83
13. Von Hoff, D. D.; LoRusso, P.; Demetri, G. D.; Weiss, G. J.; Shapiro, G.; Ramanathan, R. K.; Ware, J. A.; Raja, R.; Jin, J. Y.; Levy, G. G.; Mazina, K. E.; Wagner, A. J. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J. Clin. Oncol. 2011, 29 (2011 ASCO Annual Meeting).
14. Salphati, L.; Lee, L. B.; Pang, J.; Plise, E. G.; Zhang, X. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941 Drug Metab. Dispos. 2010, 38 (9) 1422-6
15. US Food and Drug Administration. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies; 2002.
16. Ding, X.; Morrison, G.; Dean, B.; Hop, C. E.; Tobler, L.; Percey, S.; Meng, M.; Reuschel, S.; West, D. A.; Holden, S.; Ware, J. A. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development J. Pharm. Biomed. Anal. 2012, 61, 1-7
17. Huang, S. M.; Lesko, L. J.; Williams, R. L. Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues J. Clin. Pharmacol. 1999, 39 (10) 1006-14
18. Pang, J.; Dalziel, G.; Dean, B.; Ware, J. A.; Salphati, L. Pharmacokinetics and Absorption of the Anticancer Agents Dasatinib and GDC-0941 under Various Gastric Conditions in Dogs-Reversing the Effect of Elevated Gastric pH with Betaine HCl Mol. Pharmaceutics 2013, 10.1021/mp400356m
19. US Food and Drug Administration. Rabeprazole (Aciphex) Prescribing Information; 2013.
20. US Food and Drug Administration. Erlotinib (Tarceva) Prescribing Information; 2013.
21. US Food and Drug Administration. Nilotinib (Tasigna) Prescribing Information; 2013.
22. Yago, M. R.; Frymoyer, A. R.; Smelick, G. S.; Frassetto, L. A.; Budha, N. R.; Dresser, M. J.; Ware, J. A.; Benet, L. Z. Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria Mol. Pharmaceutics 2013, 10.1021/mp4003738